X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (481) 481
Publication (63) 63
Magazine Article (7) 7
Book Chapter (2) 2
Book Review (1) 1
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (468) 468
atazanavir sulfate (395) 395
hiv infections - drug therapy (371) 371
male (302) 302
oligopeptides - adverse effects (279) 279
pyridines - adverse effects (279) 279
female (275) 275
adult (273) 273
index medicus (254) 254
middle aged (222) 222
oligopeptides - therapeutic use (222) 222
pyridines - therapeutic use (222) 222
infectious diseases (205) 205
hiv protease inhibitors - adverse effects (193) 193
atazanavir (171) 171
anti-hiv agents - adverse effects (166) 166
hiv protease inhibitors - therapeutic use (156) 156
oligopeptides - administration & dosage (154) 154
pyridines - administration & dosage (154) 154
hiv (147) 147
anti-hiv agents - therapeutic use (144) 144
drug therapy, combination (124) 124
immunology (121) 121
ritonavir - therapeutic use (121) 121
pharmacology & pharmacy (118) 118
ritonavir - adverse effects (117) 117
protease inhibitors (113) 113
antiretroviral therapy (107) 107
anti-hiv agents - administration & dosage (103) 103
ritonavir - administration & dosage (103) 103
hiv protease inhibitors - administration & dosage (101) 101
ritonavir (100) 100
treatment outcome (100) 100
viral load (92) 92
drug interactions (83) 83
hiv infections - virology (82) 82
tenofovir (78) 78
cd4 lymphocyte count (77) 77
hiv-1 - drug effects (73) 73
oligopeptides - pharmacokinetics (73) 73
pyridines - pharmacokinetics (73) 73
lopinavir (68) 68
virology (68) 68
hiv infections - complications (67) 67
microbiology (66) 66
drug therapy (65) 65
hiv infection (64) 64
pharmacokinetics (62) 62
therapy (61) 61
adenine - analogs & derivatives (57) 57
drug administration schedule (57) 57
antiviral agents (55) 55
combination (55) 55
human immunodeficiency virus--hiv (55) 55
aged (54) 54
hiv protease inhibitors - pharmacokinetics (54) 54
hiv-1 (54) 54
aids/hiv (51) 51
antiretroviral therapy, highly active (51) 51
hiv-infected patients (50) 50
antiretroviral drugs (49) 49
atazanavir sulfate - adverse effects (49) 49
young adult (49) 49
research (48) 48
atazanavir sulfate - therapeutic use (47) 47
adolescent (45) 45
antiretroviral therapy, highly active - adverse effects (45) 45
efficacy (45) 45
risk factors (45) 45
dosage and administration (43) 43
hiv infections - blood (43) 43
protease inhibitor (43) 43
rna, viral - blood (43) 43
safety (43) 43
pyridines - pharmacology (42) 42
lopinavir/ritonavir (41) 41
oligopeptides - pharmacology (41) 41
prospective studies (41) 41
anti-hiv agents - pharmacokinetics (40) 40
emtricitabine (40) 40
highly active antiretroviral therapy (40) 40
active antiretroviral therapy (38) 38
efavirenz (38) 38
retrospective studies (38) 38
care and treatment (36) 36
deoxycytidine - analogs & derivatives (36) 36
aids (35) 35
lamivudine (35) 35
ritonavir - pharmacokinetics (35) 35
pyrimidinones - adverse effects (33) 33
adenine - therapeutic use (32) 32
health aspects (32) 32
human immunodeficiency virus (32) 32
hyperbilirubinemia - chemically induced (32) 32
virus diseases (32) 32
antiretroviral therapy, highly active - methods (31) 31
proteases (31) 31
adenine - adverse effects (30) 30
drug combinations (30) 30
pyrimidinones - therapeutic use (30) 30
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Infectious Diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Major and Brief Reports
Journal Article
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2016, Volume 3, Issue 9, pp. e410 - e420
Summary Background Women are under-represented in HIV antiretroviral therapy (ART) studies. Guidelines for selection of ART as initial therapy in patients with... 
Infectious Disease | UNITED-STATES | INFECTIOUS DISEASES | TENOFOVIR DISOPROXIL FUMARATE | TREATMENT-NAIVE | ACTIVE ANTIRETROVIRAL THERAPY | CLINICAL-TRIALS | INITIAL TREATMENT | GENDER | SEX-DIFFERENCES | IMMUNOLOGY | HIV-1 INFECTION | ADVERSE EVENTS | Atazanavir Sulfate - administration & dosage | Humans | RNA, Viral - blood | Tenofovir - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Atazanavir Sulfate - adverse effects | Viral Load | Quinolones - adverse effects | Ritonavir - adverse effects | Quinolones - therapeutic use | Ritonavir - therapeutic use | Adult | Female | Emtricitabine - administration & dosage | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | Ritonavir - administration & dosage | Tenofovir - therapeutic use | HIV Infections - virology | Cobicistat - administration & dosage | International Cooperation | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Antiretroviral Therapy, Highly Active | Atazanavir Sulfate - therapeutic use | Quinolones - administration & dosage | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | Cobicistat - adverse effects | HIV Infections - drug therapy | Cobicistat - therapeutic use
Journal Article
Journal Article
Journal Article
by Slama, Laurence and Landman, Roland and Assoumou, Lambert and Benalycherif, Aida and Samri, Assia and Joly, Véronique and Pialoux, Gilles and Valin, Nadia and Cabié, André and Duvivier, Claudine and Lambert-Niclot, Sidonie and Marcelin, Anne-Geneviève and Peytavin, Gilles and Costagliola, Dominique and Girard, Pierre-Marieon and Abel, Sylvie and Hochedez, Patrick and Pierre-François, Sandrine and Rozé, Benoît and Simon, Anne and Lupin, Catherine and Katlama, Christine and Valentin, Marc Antoine and Autran, Brigitte and Lambert, Sidonie and Julia, Zélie and Harent, Stanislas and Papot, Emmanuelle and Phung, Bao-Chau and Minh, Patrick Lê and Rami, Agathe and Diemer, Myriam and Parrinello, Maguy and Cahitte, I and Zeng, Feng and Mortier, E and L'Yavanc, Thomas and Le Loup, Guillaume and Bonnard, Philippe and Lebrette, Marie Gisèle and Chas, Julie and Berrebi, Valérie and Velazquez, Nadège and Adda, Anne and Touam, Fatima and Lortholary, Olivier and Shoai-Tehrani, Michka and Rouzaud, Claire and Denes, Eric and Ducroux-Roubertou, Sophie and Durox, Hélène and Genet, Claire and Rogez, Jean-Philippe and Rogez, Sylvie and Pascual, Jose and Weiss, Laurence and Pavie, Juliette and Bourzam, Erila and Aumaître, Hugues and Ferreyra, Milagros and Saada, Matthieu and Malet, Martine and Palacios, Christia and Honore, Patricia and Zamord, Irene and Berthe, Huguette and Landowski, Stéphanie and de Truchis, Pierre and Perre, Philippe and Campa, Pauline and Lefebvre, Bénédicte and Meynard, Jean-Luc and Pauchard, Michèle and Surgers, Laure and IMEA 040 Data Study Grp and IMEA 040 DATA Study Group
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 08/2016, Volume 71, Issue 8, pp. 2252 - 2261
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, pp. e0123670 - e0123670
Introduction Ritonavir-boosted atazanavir (ATV/r) is a relatively well tolerated antiretroviral drug. However, side effects including hyperbilirubinemia,... 
UNBOOSTED ATAZANAVIR | BILIRUBIN | HYPERBILIRUBINEMIA | EFFICACY | PHARMACOKINETICS | TOLERABILITY | MULTIDISCIPLINARY SCIENCES | ANTIRETROVIRAL THERAPY | RENAL STONES | POLYMORPHISM | RITONAVIR-BOOSTED ATAZANAVIR | Nephrolithiasis - chemically induced | Atazanavir Sulfate - administration & dosage | Humans | Middle Aged | Male | Atazanavir Sulfate - adverse effects | Atazanavir Sulfate - pharmacokinetics | Drug Dosage Calculations | Dyslipidemias - blood | HIV-1 - physiology | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Hyperbilirubinemia - chemically induced | Adult | Female | Hyperbilirubinemia - physiopathology | Nephrolithiasis - physiopathology | Dyslipidemias - diagnosis | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Atazanavir Sulfate - blood | Drug Administration Schedule | Hyperbilirubinemia - diagnosis | HIV-1 - drug effects | HIV Infections - virology | Nephrolithiasis - blood | HIV Protease Inhibitors - administration & dosage | Nephrolithiasis - diagnosis | Antiretroviral Therapy, Highly Active | Hyperbilirubinemia - blood | Dyslipidemias - chemically induced | HIV Infections - drug therapy | Drug Monitoring | Viral Load - drug effects | Dyslipidemias - physiopathology | Highly active antiretroviral therapy | HIV patients | HIV (Viruses) | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Toxicity | Ritonavir | Complications | Dyslipidemia | Lipids | Nephrolithiasis | Dosage | Patients | Side effects | Hyperbilirubinemia | Acquired immune deficiency syndrome--AIDS | Protease inhibitors | Antiretroviral agents | Human immunodeficiency virus--HIV | All terrain vehicles | Index Medicus | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article